Marico Ltd

Marico Ltd maintains a strong liquidity position, with cash and equivalents amounting to INR 9.43 billion, representing 24.6% of total assets. The company's liquidity FPT (free cash flow to total liabilities) is robust, supported by an operating cash flow of INR 13.87 billion and a current ratio of 1.64. The debt-to-equity ratio of 0.14 indicates a conservative capital structure, with long-term debt at INR 5.28 billion and total equity at INR 38.32 billion. Profitability metrics show Marico is outperforming the industry median in return on equity (ROE) at 8.3%, which is above the Food Processing industry's typical ROE of 6.5%. Return on assets (ROA) of 4.29% is also in line with the sector average. Gross margin of 51.6% and operating margin of 17.6% are both above the industry median, indicating efficient cost management and pricing power. Geographically, Marico's revenue is heavily concentrated in India, with no material international operations disclosed. The company's business is segmented into edible oils, personal care, and other food products. The edible oils segment accounts for the largest share of revenue, with a strong brand presence in the Indian market. Looking ahead, Marico is projected to grow revenue by 6.2% in the current fiscal year and 4.8% in the next, driven by expansion in the personal care segment and continued market share gains in edible oils. The company's capital expenditure of INR 1.53 billion is modest relative to operating cash flow, suggesting a focus on maintaining rather than expanding physical assets. Risk factors for Marico include low liquidity risk and low dilution potential, with no immediate filing-based flags detected. The company's diluted shares outstanding are equal to basic shares, indicating no near-term dilution pressure. The risk assessment composite score is low, with no significant financial or operational red flags identified. Recent events include a Q4 earnings report that exceeded analyst expectations, with net income of INR 3.18 billion. The company also announced a new product launch in the personal care segment, targeting the premium market. Analysts have maintained a positive outlook, with a mean price target of INR 850.18 and a median recommendation of 1.87 (leaning toward buy).